|
1
|
Permuth-Wey J and Sellers TA: Epidemiology
of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gayther SA and Pharoah PD: The inherited
genetics of ovarian and endometrial cancer. Curr Opin Genet Dev.
20:231–238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seto E and Yoshida M: Erasers of histone
acetylation: The histone deacetylase enzymes. Cold Spring Harb
Perspect Biol. 6:a0187132014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Verdin E, Dequiedt F and Kasler HG: Class
II histone deacetylases: Versatile regulators. Trends Genet.
19:286–293. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Higashijima J, Kurita N, Miyatani T,
Yoshikawa K, Morimoto S, Nishioka M, Iwata T and Shimada M:
Expression of histone deacetylase 1 and metastasis-associated
protein 1 as prognostic factors in colon cancer. Oncol Rep.
26:343–348. 2011.PubMed/NCBI
|
|
6
|
Miyake K, Yoshizumi T, Imura S, Sugimoto
K, Batmunkh E, Kanemura H, Morine Y and Shimada M: Expression of
hypoxia-inducible factor-1alpha, histone deacetylase 1, and
metastasis-associated protein 1 in pancreatic carcinoma:
Correlation with poor prognosis with possible regulation. Pancreas.
36:e1–e9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Minamiya Y, Ono T, Saito H, Takahashi N,
Ito M, Mitsui M, Motoyama S and Ogawa J: Expression of histone
deacetylase 1 correlates with a poor prognosis in patients with
adenocarcinoma of the lung. Lung Cancer. 74:300–304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khabele D, Son DS, Parl AK, Goldberg GL,
Augenlicht LH, Mariadason JM and Rice VM: Drug-induced inactivation
or gene silencing of class I histone deacetylases suppresses
ovarian cancer cell growth: Implications for therapy. Cancer Biol
Ther. 6:795–801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weichert W, Denkert C, Noske A,
Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG and Köbel M:
Expression of class I histone deacetylases indicates poor prognosis
in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasia. 10:1021–1027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayashi A, Horiuchi A, Kikuchi N, Hayashi
T, Fuseya C, Suzuki A, Konishi I and Shiozawa T: Type-specific
roles of histone deacetylase (HDAC) overexpression in ovarian
carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates
cell migration with downregulation of E-cadherin. Int J Cancer.
127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sonnemann J, Gänge J, Pilz S, Stötzer C,
Ohlinger R, Belau A, Lorenz G and Beck JF: Comparative evaluation
of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA)
and paclitaxel in ovarian cancer cell lines and primary ovarian
cancer cells from patients. BMC Cancer. 6:1832006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Modesitt SC, Sill M, Hoffman JS and Bender
DP; Gynecologic Oncology Group, : A phase II study of vorinostat in
the treatment of persistent or recurrent epithelial ovarian or
primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol. 109:182–186. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamaguchi T, Cubizolles F, Zhang Y,
Reichert N, Kohler H, Seiser C and Matthias P: Histone deacetylases
1 and 2 act in concert to promote the G1-to-S progression. Genes
Dev. 24:455–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zupkovitz G, Grausenburger R, Brunmeir R,
Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G,
Lagger S, et al: The cyclin-dependent kinase inhibitor p21 is a
crucial target for histone deacetylase 1 as a regulator of cellular
proliferation. Mol Cell Biol. 30:1171–1181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH,
Choi J, Ro S, Hyun YL, Lee JS and Kim CS: A novel histone
deacetylase inhibitor, CG0006, induces cell death through both
extrinsic and intrinsic apoptotic pathways. Anticancer Drugs.
20:815–821. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoo YG, Kong G and Lee MO:
Metastasis-associated protein 1 enhances stability of
hypoxia-inducible factor-1alpha protein by recruiting histone
deacetylase 1. EMBO J. 25:1231–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ray A, Alalem M and Ray BK: Loss of
epigenetic Kruppel-like factor 4 histone deacetylase
(KLF-4-HDAC)-mediated transcriptional suppression is crucial in
increasing vascular endothelial growth factor (VEGF) expression in
breast cancer. J Biol Chem. 288:27232–27242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Woods DM, Sodre AL, Villagra A, Sarnaik A,
Sotomayor EM and Weber J: HDAC Inhibition upregulates PD-1 ligands
in melanoma and augments immunotherapy with PD-1 blockade. Cancer
Immunol Res. 3:1375–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang H, Yan B, Liao D, Huang S and Qiu Y:
Acetylation of HDAC1 and degradation of SIRT1 form a positive
feedback loop to regulate p53 acetylation during heat-shock stress.
Cell Death Dis. 6:e17472015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ni T, Li XY, Lu N, An T, Liu ZP, Fu R, Lv
WC, Zhang YW, Xu XJ, Grant Rowe R, et al: Snail1-dependent p53
repression regulates expansion and activity of tumour-initiating
cells in breast cancer. Nat Cell Biol. 18:1221–1232. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: Loss of ARID1A protein expression occurs as an early
event in ovarian clear-cell carcinoma development and frequently
coexists with PIK3CA mutations. Mod Pathol. 25:615–624. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bitler BG, Wu S, Park PH, Hai Y, Aird KM,
Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ III, et al:
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell
Biol. 19:962–973. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ketabi Z, Bartuma K, Bernstein I, Malander
S, Grönberg H, Björck E, Holck S and Nilbert M: Ovarian cancer
linked to Lynch syndrome typically presents as early-onset,
non-serous epithelial tumors. Gynecol Oncol. 121:462–465. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jensen KC, Mariappan MR, Putcha GV, Husain
A, Chun N, Ford JM, Schrijver I and Longacre TA: Microsatellite
instability and mismatch repair protein defects in ovarian
epithelial neoplasms in patients 50 years of age and younger. Am J
Surg Pathol. 32:1029–1037. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang M, Xiang S, Joo HY, Wang L, Williams
KA, Liu W, Hu C, Tong D, Haakenson J, Wang C, et al: HDAC6
deacetylates and ubiquitinates MSH2 to maintain proper levels of
MutSα. Mol Cell. 55:31–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyazawa M, Yasuda M, Fujita M, Hirasawa
T, Kajiwara H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H,
Murakami M, et al: Association of hypoxia-inducible factor-1
expression with histology in epithelial ovarian tumors: A
quantitative analysis of HIF-1. Arch Gynecol Obstet. 279:789–796.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kato H, Tamamizu-Kato S and Shibasaki F:
Histone deacetylase 7 associates with hypoxia-inducible factor
1alpha and increases transcriptional activity. J Biol Chem.
279:41966–41974. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B,
Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, et al:
Identification of a cancer stem cell-specific function for the
histone deacetylases, HDAC1 and HDAC7, in breast and ovarian
cancer. Oncogene. 36:1707–1720. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu MY, Fu J, Xiao X, Wu J and Wu RC:
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7
in breast cancer. Cancer Lett. 354:311–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ai Z, Lu Y, Qiu S and Fan Z: Overcoming
cisplatin resistance of ovarian cancer cells by targeting
HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin CT, Lai HC, Lee HY, Lin WH, Chang CC,
Chu TY, Lin YW, Lee KD and Yu MH: Valproic acid resensitizes
cisplatin-resistant ovarian cancer cells. Cancer Sci. 99:1218–1226.
2008. View Article : Google Scholar : PubMed/NCBI
|
